Popular terms

Leukemia topics
Myelogenous
Myelogenous Leukemia
Proliferative
Autoimmune
Stem Cells
Breast Cancer
Rheumatoid Arthritis
Myeloid Leukemia
Acute Myelogenous Leukemia
Lymphocytic
Chronic Lymphocytic Leukemia
Lymphocytic Leukemia
Epigenetic
Multiple Myeloma
Polyphenol

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Leukemia patents



      

This page is updated frequently with new Leukemia-related patent applications.




Date/App# patent app List of recent Leukemia-related patents
05/19/16
20160138115 
 Methods and characteristics for the diagnosis of acute lymphoblastic leukemia patent thumbnailMethods and characteristics for the diagnosis of acute lymphoblastic leukemia
Methods for identification of leukemia or a genetic predisposition to leukemia are provided that are particularly applicable to acute lymphoblastic leukemia (all). A novel heterozygous germline variant, c.547g>a (p.gly183ser) in the octapeptide domain of pax5, is used to identify those individuals with an enhanced risk or predisposition to all..
Memorial Sloan-kettering Cancer Center


05/19/16
20160137630 
 Induction of gata2 by hdac1 and hdac2 inhibitors patent thumbnailInduction of gata2 by hdac1 and hdac2 inhibitors
Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with gata2 deficiency, particularly diseases or disorders that involve any type of hdac1 and/or hdac2 expression. Such diseases include acute myeloid leukemia (aml); familial myelodysplastic syndrome (mds); leukemia; sickle-cell anemia; beta-thalassemia; monocytopenia and mycobacterial infections; dendritic cell, nonocyte, b, and natural killer lymphoid deficiency; emberger syndrome; asymptomatic neurocognitive impairment; mild neurocognitive disorder; and hiv-associated dementia..
Acetylon Pharmaceuticals, Inc.


05/19/16
20160136218 
 Molecular and herbal combinations for disease therapy patent thumbnailMolecular and herbal combinations for disease therapy
A method and medicine for treating leukemia or other cancer includes administering to a patient diagnosed with leukemia or other cancer a treatment regimen that includes periodic doses of a combination including emodin or digoxin, or both, with sheng di huang or da huang, or both, and/or jin yin hua.. .
Sirbal Ltd.


05/12/16
20160131654 
 Diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma patent thumbnailDiagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma
The invention generally provides improved compositions and methods for detecting, diagnosing, prognosing, and monitoring multiple myeloma, chronic lymphocytic leukemia, or b-cell non-hodgkin lymphoma in a subject. In particular, the invention provides methods for detecting bcma in subjects to reliably diagnose, predict survival, or monitor multiple myeloma, chronic lymphocytic leukemia, or b-cell non-hodgkin lymphoma in the subject..
Institute For Myeloma & Bone Cancer Research


05/12/16
20160130665 
 Prognostic methods and systems for chronic lymphocytic leukemia patent thumbnailPrognostic methods and systems for chronic lymphocytic leukemia
The present invention provides systems useful for risk stratification of chronic lymphocytic leukemia (cll) patients. The systems can include a microarray and a decision tree having steps for stratification of one or more cll patients into prognostic groups.
Cancer Genetics, Inc.


05/12/16
20160130659 
 Compositions and methods for treating cancer patent thumbnailCompositions and methods for treating cancer
The instant invention relates to methods for the treatment of b-cell lymphomas and leukemia by administering a syk inhibitor. In another embodiment, the invention relates to a method for treating a patient diagnosed with a b-cell lymphoma or leukemia, comprising administering a syk inhibitor, wherein the b-cells of said patient to be treated are characterized by elevated expression levels of cd86..
Merck Sharp & Dohme Corp.


05/12/16
20160130582 
 Oligonucleotide modulators of b-cell cll/lymphoma 11a (bcl11a) and uses thereof patent thumbnailOligonucleotide modulators of b-cell cll/lymphoma 11a (bcl11a) and uses thereof
The present invention provides, among other things, oligonucleotide modulators (e.g., inhibitors) of b cell lymphoma/leukemia 11a (bcl11a) and improved methods and composition for treating bcl11a-related diseases, disorders or conditions based on such modulators.. .
Roche Innovation Center Copenhagen A/s


05/12/16
20160130317 
 Il-12 immunotherapy for cancer patent thumbnailIl-12 immunotherapy for cancer
Compositions and methods for delivering immune modulatory molecules to result in a therapeutic effect are disclosed. The compositions and methods use stably integrating lentiviral delivery systems.
University Health Network


05/05/16
20160122334 
 Inhibitors of c-fms kinase patent thumbnailInhibitors of c-fms kinase
Wherein z, x, j, r2 and w are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of formula i, are also provided..

05/05/16
20160122323 
 Inhibitors of cyclin-dependent kinase 7 (cdk7) patent thumbnailInhibitors of cyclin-dependent kinase 7 (cdk7)
The present invention provides novel compounds of formula (i), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, lymphoma, melanoma, multiple myeloma, breast cancer, ewing's sarcoma, osteosarcoma, brain cancer, neuroblastoma, lung cancer), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject.
Dana-farber Cancer Institute, Inc.


04/28/16
20160115468 

Albumin-binding arginine deiminase for cancer targeting treatment and detection of arginine


The present invention provides a pharmaceutical composition containing albumin-binding arginine deiminase (aad) fusion protein for treating cancer or other arginine-dependent diseases. The aad fusion protein can be purified from both soluble and insoluble fractions of crude proteins, it binds to human serum albumin (hsa) or animal serum albumin and has its high activity with longer half life for efficient depletion of arginine in cancer cells.
Vision Global Holdings Ltd.


04/28/16
20160115238 

Cd20 antibodies and uses thereof


Cd20 is a transmembrane protein of the tetra-spanin family expressed on the surface of b-cells from peripheral blood as well as lymphoid tissues. Cd20 expression persists from the early pre-b cell stage until the plasma cell differentiation stage.
Immunogen, Inc.


04/28/16
20160114018 

Imp-3 epitope peptides for th1 cells and vaccines containing the same


Isolated imp-3-derived epitope peptides having th1 cell inducibility are disclosed herein. Such peptides can be recognized by mhc class ii molecules and induce th1 cells.
Oncotherapy Science, Inc.


04/21/16
20160108477 

Traceability of cellular cycle anomalies targeting oncology and neurodegeneration


The present invention relates to the field of medicine and biology. It concerns a novel test for screening and for therapeutic follow-up in oncology.

04/21/16
20160108360 

Genetic modification of rats


Compositions and methods are provided for making rat pluripotent and totipotent cells, including rat embryonic stem (es) cells. Compositions and methods for improving efficiency or frequency of germline transmission of genetic modifications in rats are provided.

04/21/16
20160108126 

Cd20 antibodies and uses thereof


Cd20 is a transmembrane protein of the tetra-spanin family expressed on the surface of b-cells from peripheral blood as well as lymphoid tissues. Cd20 expression persists from the early pre-b cell stage until the plasma cell differentiation stage.

04/21/16
20160108033 

Histone demethylase inhibitors


The present invention relates generally to compositions and methods for treating cancer and neoplastic diseases. Provided herein are substituted imidazole-pyridine derivative compounds and pharmaceutical compositions comprising said compounds.

04/21/16
20160108031 

Inhibitors of nhr2 and/or runx1/eto-tetramerization


The invention relates to inhibitors of the nhr2 tetramerization and their use as tumor therapeutics (e.g. Against acute myeloid leukemia (aml)), cytostatics, and diagnostic agents..

04/21/16
20160106731 

Tricyclic indole mcl-1 inhibitors and uses thereof


The present invention provides for compounds that inhibit the activity of an anti-apoptotic bcl-2 family member myeloid cell leukemia-1 (mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of mcl-1 protein..

04/07/16
20160097770 

Methods for diagnosis, prognosis and methods of treatment


This invention is directed to methods and compositions for diagnosis, prognosis and for determining methods of treatment. The physiological status of cells present in a sample (e.g.
Nodality, Inc.


04/07/16
20160096825 

Furanone compounds as kinase inhibitors


The present disclosure provides novel furanone compounds, or pharmaceutically acceptable salts, solvates or prodrugs thereof, as raf kinase, especially braf kinase, inhibitors, which are useful therapeutic agents for treatment of raf kinase related diseases or disorders, such as melanomas, cancers, and leukemia. The disclosure also provides methods and processes for preparing these novel furanone compounds, pharmaceutical compositions containing these furanone compounds, and methods of treatment using these furanone compounds..
Eternity Bioscience Inc.


04/07/16
20160096820 

Inhibitors of inv(16) leukemia


This invention describes the development of targeted small molecule inhibitors of the inv(16) fusion, the causative agent in ˜12% of acute myeloid leukemia (aml). The inv(16) fusion results in expression of the cbfβ-smmhc fusion protein in the blood cells of afflicted patients.
University Of Virginia Patent Foundation


04/07/16
20160095870 

Methods of forming cyclopirox or derivatives thereof in a subject by administration of prodrug


A method of forming a compound in a subject can include: providing a composition having a prodrug compound represented by a structure of formula 1 or stereoisomer thereof or pharmaceutically acceptable salt thereof; and administering the composition to a subject such that the prodrug compound has a phosphoryloxyalkyl prodrug moiety removed therefrom to form the compound in the subject and to form the separate phosphoryloxyalkyl compound. The prodrug can be included in a pharmaceutical composition for use in treatment of fungus, various cancers (e.g., bladder, breast, etc.), dermatitis, superficial mycoses; inflammation, tinea pedis, tinea cruris, and tinea corporis, trichophyton rubrum, trichophyton mentagrophytes, epidermophyton floccosum, and microsporum canis, candidiasis (moniliasis), candida albicans, tinea (pityriasis) vesicolor, malassezia furfur, acute myeloid leukemia, acute lymphoid leukemia, chronic myelogenous leukemia, lymphoma or multiple myeloma..
The University Of Kansas


04/07/16
20160095863 

Combination treatment of acute myeloid leukemia and myelodysplastic syndrome


The present invention relates to the use of volasertib or a salt thereof or the hydrate thereof in combination with quizartinib or a salt thereof or the hydrate thereof for treating patients suffering from acute myeloid leukemia (aml) or myelodysplastic syndrome (mds).. .
Boehringer Ingelheim International Gmbh


03/31/16
20160090637 

Pharmacogenomic biomarkers for b cell malignancies and methods of use thereof


The present invention relates to diagnosing drug-resistant chronic lymphocytic leukemia (cll) in a mammal.. .

03/24/16
20160083361 

Inhibitors of the ire-1/xbp-1 pathway and methods of using thereof


Disclosed are xbp-1/ire-1 inhibitors having formula disclosed herein. Methods of making and using these inhibitors for the treatment of cancer, in particular b cell cancers, are also disclosed.
H. Lee Moffitt Cancer Center And Research Institute, Inc.


03/24/16
20160082071 

Methods of treating myeloid leukemia


There is provided a method of treating a myeloid leukemia. The method includes the step of administering to a subject in need thereof a therapeutically effective amount of a cxcr4-antagonistic peptide and a therapeutically effective amount of a chemotherapeutic agent..
Biokine Therapeutics Ltd.


03/24/16
20160081979 

Method for separating therapeutic agent for chronic myelogenous leukemia from bark of liriodendron tulipifera l.


The present invention provides a method for separating and preparing a therapeutic agent for chronic myelogenous leukimeia capable of effectively inhibiting growth of t315i, which is known as a mutation of a bcr-abl fusion gene that causes chronic myelogenous leukemia, comprising the steps of: 1) preliminary extracting by adding ethyl acetate to finely chopped bark of liriodendron tulipifera l., adding butanol to an extracted fluid for layer-separating an ethyl acetate layer and a butanol layer, removing the butanol layer, and decompression-condensing the remainder to obtain a crude extract; and 2) adding a c1-c3 lower alcohol aqueous solution and n-hexane to the obtained crude extract, removing lipids and water insoluble material dissolved in the n-hexane layer, and obtaining and separating a lower alcohol aqueous solution layer to separate and refine highly pure epi-tulipinolide and costunolide.. .
Cho Dang Pharm. Co., Ltd.


03/24/16
20160081978 

Pharmaceutical composition containing liriodendron tulipifera l. extract for treating chronic myelogenous leukemia


The present invention relates to a pharmaceutical composition containing, as an active ingredient, a liriodendron tulipifera l. Bark extract for treating chronic myelogneous leukemia.
Cho Dang Pharm. Co., Ltd.


03/24/16
20160081973 

Activator of mitochondria


In order to allow differentiation induction of cancer cells into normal cells, the present invention provides an activator of mitochondria containing a component expected to have an epigenetic action, or provides a cell differentiation inducer having a novel composition that has an action to activate mitochondria. The activator of mitochondria contains, as an effective component, 0.03 to 300 μg/ml of a single component of kaempferol, or a mixture component of kaempferol and glycerol.
Flora Co., Ltd.


03/10/16
20160070852 

Prognosis prediction for acute myeloid leukemia by a 3-microrna scoring method


The present invention relates to a scoring method for predicting the survival of a de novo aml patient based on the expression level of micrornas mir-9, mir-155 and mir-203 in the patient. Patients with higher scores are associated with shorter overall survival.
National Taiwan University


03/10/16
20160068610 

Glutamate dehydrogenase in idh1- and idh2-mutated cancers


Expression of glud1, glud2, or both is tested in gliomas, leukemias, or suspected gliomas and leukemias. Up-regulation of expression is found in idh1/idh2 mutant cancers.
Duke University


03/10/16
20160067336 

Methods for treating a disease or disorder using oral formulations of cytidine analogs in combination with an anti-pd1 or anti-pdl1 monoclonal antibody


The present disclosure provides methods of treating diseases or disorders with oral cytidine analogs (e.g., 5-azacytidine) in combination with anti-pd1/anti-pdl1 antibodies (e.g., pembrolizumab or durvalumab). The diseases or disorders include, but are not limited to, relapsed or refractory myelodysplastic syndromes, acute myeloid leukemia, ovarian cancer, or non-small cell lung cancer..
Celgene Corporation


03/10/16
20160067240 

Novel allosteric inhibitors of thymidylate synthase


The current invention is directed to a class of compounds that inhibit the function of thymidylate synthase. Thymidylate synthase inhibition was noted to result in inhibition of tumor cell grow and killing of tumor cells.
University Of Florida Research Foundation, Inc.


03/03/16
20160060709 

Novel biomarkers for acute myeloid leukemia


Methods for the diagnosis of leukemias, and more specifically aml, such as mll-af9 aml, in a subject, based on the assessment of the expression or activity of one or more of the genes listed in tables 1 and 2 are disclosed. The use of antibodies or antigen-binding fragments thereof that bind to one or more of proteins showing preferential expression at the cell surface of aml leukemic cells for treating aml is also disclosed..
UniversitÉ Laval


03/03/16
20160060613 

Pegylated l-asparaginase


Disclosed is a conjugate of a protein having substantial l-asparagine aminohydrolase activity and polyethylene glycol. In particular, the polyethylene glycol has a molecular weight less than or equal to about 5000 da and the protein is an l-asparaginase from erwinia.
Alize Pharma Ii Sas


03/03/16
20160060342 

Markers of acute myeloid leukemia stem cells


Markers of acute myeloid leukemia stem cells (amlsc) are identified. The markers are differentially expressed in comparison with normal counterpart cells, and are useful as diagnostic and therapeutic targets..
The Board Of Trustees Of The Leland Stanford Junior University




Leukemia topics: Myelogenous, Myelogenous Leukemia, Proliferative, Autoimmune, Stem Cells, Breast Cancer, Rheumatoid Arthritis, Myeloid Leukemia, Acute Myelogenous Leukemia, Lymphocytic, Chronic Lymphocytic Leukemia, Lymphocytic Leukemia, Epigenetic, Multiple Myeloma, Polyphenol

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Leukemia for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Leukemia with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.2172

5377

1 - 1 - 102